Jan Koster (AMC), Louis Stancato (Eli Lilly).
Co-lead: Natalie Jäger (DKFZ)
Information technology infrastructure and data analysis
Centralized data repository including results of the project such as precompetitive model characteristics (i.e., all data associated with model molecular and pharmacological characterization using commercially-available agents) and SOC testing data with custom informatics tools to visualize and analyze data.
For dissemination of processed genomics and drug-testing data, the consortium proposes to build on the existing IT infrastructure that is available at the AMC (R2; r2.amc.nl) and which is used extensively in the pediatric cancer research community. R2 already has an extensive track record in providing biomedical researchers insight into their high-throughput data (390+ Pubmed citations and serving data on 100,000+ samples, Aug. 2016). R2 allows for many different types of investigations on pre-processed genomics data ranging from correlative/differential analyses up to working with whole genome sequencing results in real-time. It contains a wealth of analysis and visualizations that are easily accessible. In addition, R2 hosts a growing set of tools for integrative analyses over different types of data (e.g. correlating gene expression to DNA methylation, DNA copy-number, or mutation status). R2 will host pre-processed genomics data in various ways to allow for ‘browsing’, analysis, and visualization of the diverse types of information obtained throughout this project.
Overview of R2: Genomics Analysis and Visualization Platform – Left panel: Data storage types within the platform. Right panel: Example data visualization and correlation capabilities for mRNA data.